Morgan Stanley lowers China Grand Pharmaceutical and Healthcare Holdings Ltd. (01177) target price to 7.8 Hong Kong dollars, with a rating of "overweight".
Updated China Biopharmaceuticals (01177) predicts that the revenue contribution of the newly introduced authorized bepirovirsen (HBV ASO) is expected to start from 2027.
Morgan Stanley has released a research report stating that it has updated its forecast for CSPC Pharmaceutical Group Limited (01177), including the new introduction of bepirovirsen (HBV ASO), and expects this product to contribute revenue starting from 2027. At the same time, based on guidance from management, the assumed dividend income from Sinovac LS will be removed from 2026 onwards. Therefore, earnings per share forecasts for 2026 to 2028 have been lowered by 8%, 7%, and 7% respectively. In addition, adjustments have been made to operating working capital and capital expenditure assumptions to better reflect recent operating trends. The target price has been revised down from HK$8.3 to HK$7.8, with a rating of "hold."
Related Articles
BHCC HOLDING (01552): Zhang Jinting has been appointed as the company secretary.
REMEGEN (09995) is planning to use 300 million yuan of idle capital to purchase financial products from the Yantai Branch of Shanghai Pudong Development Bank.
YUEXIUTRANSPORT(01052): "25 YUE TO 01" will pay interest on June 9th.
BHCC HOLDING (01552): Zhang Jinting has been appointed as the company secretary.
REMEGEN (09995) is planning to use 300 million yuan of idle capital to purchase financial products from the Yantai Branch of Shanghai Pudong Development Bank.
YUEXIUTRANSPORT(01052): "25 YUE TO 01" will pay interest on June 9th.
